Navigation Links
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Date:6/8/2009

Overview of 11 peer review publications presented in 'Future Oncology'

SEATTLE, June 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reports a summary of peer reviewed publications spanning preclinical, Phase I and Phase II clinical studies with pixantrone was reviewed in the May 2009 edition of Future Oncology (Volume 5, Issue 4) which is now available on line. The article, "Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas," was written by Drs. Barry W. Hancock and Loaie M. El-Helw of the Weston Park Hospital, Sheffield UK.

The review focuses on the impressive preclinical anti-tumor activity demonstrated in hematologic cancers over standard anthracyclines and the rational design modifications to the chemical compound believed to be responsible for enhanced DNA damage and binding to topoisomerase II enzyme, a key target for anthracycline mediated tumor death. These modifications are also hypothesized by the authors to underlie the drugs' low cardiotoxicity profile in preclinical animal studies when compared to standard anthracycline drugs.

Five phase I/II studies in which pixantrone was added to standard chemotherapy regimens for treating relapsed aggressive and indolent NHL were also reviewed in the article. Pixantrone, when added to standard multi-agent chemotherapy regimens produced encouragingly high rates of overall response (58-74%) including high rates of complete responses (37-57%). As previously reported, neutropenia was the dose limiting toxicity when used as a single agent.

"In both preclinical and early clinical studies pixantrone exhibited lower cardiac toxicity and better anti-tumor activity than that observed with alternative anthracyclines, as it is devoid of the putative cardiac toxicity generating chemical structure," said Barry W. Hancock, M.D., Professor of Medical Oncology
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
10. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
11. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market ... Scanner Industry, 2009-2019 is a professional and in-depth ... Crystallography Scanner industry . The report firstly reviews ... its classification, application and manufacturing technology. The report ... X-Ray Crystallography Scanner listing their product specification, capacity, ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... SAN DIEGO, Oct. 2 Pharmatek Laboratories, Inc., a ... industry, announced that it is the first CRO on ... the company,s preclinical and early phase clinical GMP supply ... move our customers, drug candidates into the clinic more ...
... The next major personalized medicine advances will create therapies that ... health care industry to gain access, the inventor of the ... Medical Center,s Personalized Health Care National Conference ... for Systems Biology, said personalized medicine,s first "killer apps" - ...
Cached Medicine Technology:Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast 2Personalized Medicine 'Killer Apps' Will Transform Care Model 2
(Date:8/29/2014)... As reported by GantDaily.com in the article ... , Outbreaks (8/20), the National Institute on Drug Abuse is ... trends by turning to social media. As NIDA currently relies ... also working with the University of Maryland to create a ... which will be funded by the National Institute of Health. ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by the ... By Drug Court Grad (8/17), a graduate of the Frederick ... back after his own experience with the program. The graduate, Korey ... also includes a 1 mile walk. He plans to donate the ... well as to those who helped him. Shorb, who graduated in ...
(Date:8/29/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Glass microfiber including ... then explores global and China’s top manufacturers of ... value, and market share etc. , The report ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... G. Rodas. Dr. Rodas will be practicing out of ... As a member of Healthpointe’s orthopedic team, ... internal medicine, and board-certified in occupational medicine. , ... title as Medical Director of Raytheon, the world-class defense ...
(Date:8/29/2014)... Dr. Parsa Mohebi M.D. has developed new techniques ... great results in hair transplantation. One of these techniques ... FUE method that harvests facial hair for transplanting to the ... whose hair loss classification is 5 and above achieve reasonable ... alternative for those advanced hair loss patients who may not ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2
... ... Open in Late 2008, BETHESDA, Md., Feb. 19 Fox ... Living, Inc. (NYSE: SRZ ), continues to thrive during one ... already,been reserved to date and construction on the community is at ...
... revolution taking place,and it,s changing the face of cold-beverage ... that,s more sophisticated than traditional,sodas. Many are looking for ... past, finding a healthy and delicious bottled,drink was no ... are,definitely something to get excited about., "The beverage ...
... CHARLOTTE, N.C., Feb. 19 MedCath Corporation,(Nasdaq: ... has entered into,a new strategic relationship with Solaris ... LLC, will participate in a new venture to ... hospitals, JFK,Medical Center and Muhlenberg Regional Medical Center. ...
... 19 With Presidential,candidates campaigning -- and smiling ... Michael Kosdon has had ample opportunity to,judge their ... has,picked a winner., "I would definitely say ... than Hillary Clinton," says Kosdon, who has,transformed hundreds ...
... Inc., the worldwide leader,in handheld X-ray technologies, today ... available. The NOMAD Pro builds upon,the heritage of ... http://www.newscom.com/cgi-bin/prnh/20080219/LATU057 ), "The NOMAD has forever changed ... an operator to safely stay in the room ...
... medication, error prevention outreach and education for HIMSS attendees wearing custom ... ... BRUNO, Calif., Feb. 19 First DataBank, a leading,provider of drug ... to focus public and industry attention on the,prevention of medication errors. ...
Cached Medicine News:Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 2Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 3Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 4Health News:The Search for Healthier Drinks Turns Up Yerba Mate 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 3Health News:Smiling on the Campaign Trail - Cosmetic Dentist Michael Kosdon Rates the Candidates 2Health News:Aribex Unveils New Handheld Intraoral X-ray System - NOMAD Pro 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 3
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
... II (Low Melt), A low temperature ... melting temperature , Optimal for in-gel restriction ... forms a very manageable clear gel that ... Melts at approximately 65°C and remains fluid ...
... Agarose, Molecular Biology Grade, is ... of nucleic acids. It can ... fragments from 0.2 to 40 ... Agarose is tested and certified ...
Medicine Products: